Through our network of global connections, we aim to make knowledge not just available, but valuable. We want to help you acquire expertise that can be directly applied to your practice. Explore the various medical education resources below:
CAR-T Course: Regulatory Aspects of Immunotherapy
The latest course in the EHA CAR-T Program is now available: Regulatory Aspects of Immunotherapy. This course explores the regulatory processes for evaluation and authorization of medicines in the EU, with a special focus on innovative and biologic drugs. The pathways of regular and accelerated marketing authorizations and post-marketing surveillance are also covered.
CAR-T cell therapy in the real world (EHA25 Virtual)
Managing complex CAR-T cell treatments in the clinical practice may be challenging, however, several real-world data are currently available. Listen to Catherine Thieblemont discussing the main issues of CAR-T therapy delivery and results in the real life during the past EHA25 Virtual congress.
T-cell engaging antibodies for hematological diseases from approved therapies to...
Are bispecific antibodies less effective (and less toxic) than CAR-T cells? This educational video from EHA25 congress shows us the race between CAR-T therapy and bispecific Abs for hematological diseases is still ongoing!
EHA25: The Present and Future of T cell-based Immunotherapy
A selection of videos from EHA25 are now available on the European Immunotherapy Net. In this article, presentations covering the increasingly growing field of T cell-based immunotherapy are shared.
ASH Educational Highlights: Focus on Immunotherapy
We've selected a series of educational papers from the ASH Educational Program, covering different aspects of immunology and immunotherapy in lymphomas, leukemias and myeloma.
EHA-SWG Scientific Meeting on Immunotherapy: Multiple Myeloma - More than CAR-T
This selection of educational videos from the recent EHA-SWG Scientific Meeting on Immunotherapy address the latest and more innovative immune-therapeutic options for multiple myeloma patients - including bispecific antibodies, antibody-drug-conjugates and new immunomodulator drugs.
New module from the EHA CAR-T Program: CAR-T therapy for hematopoietic malignanc...
This new course covers indications of CAR-T therapy, from the more common ones to the newest. Landmark trials are briefly covered, but also preliminary studies in diseases such as CLL. Barriers to CAR-T and patient selection issues complete the course.
EHA CAR-T Program
An 8-course program covering all aspects of CAR-T; mechanisms of action, the process of CAR-T manufacture and infusion, treatment of hematopoietic malignancies and patient selection, CRS, and other complications as well as ethics and consent, multidisciplinary care and regulatory aspects.
EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologi...
Selected from the latest EHA-SWG Scientific Meeting on Immunotherapy, we present two lectures covering the use of immune checkpoint inhibitors (ICIs) in hematology. Peter Brossart explains the mechanism of action of these drugs and Paul Bröckelmann gives an updated overview of approved and emerging indications.
A Primer on CAR-T Therapy: What Does It Mean for Pathologists?: A Summary Guidan...
The College of American Pathologists Personalized Health Care Committee developed a summary guidance paper to educate pathologists on CAR-T and chimeric antigen receptor-derived cellular therapy, provide a better understanding of their role in this process, explain important regulatory aspects of CAR-T therapy, and advocate for pathologist involvement in the delivery and monitoring of CAR-based treatment.